In vivo evaluation of a transdermal codrug of 6-β-naltrexol linked to hydroxybupropion in hairless guinea pigs

European Journal of Pharmaceutical Sciences

Volumn 33, Issue 4-5, 2008, Pages 371-379

  Kiptoo, Paul K ^a   Paudel, Kalpana S ^a   Hammell, Dana C ^a   Hamad, Mohamed O ^a   Crooks, Peter A ^a   Stinchcomb, Audra L ^a  

^a University of Kentucky   (United States)

Author keywords

6 Naltrexol; Bioconversion; Codrug; Hairless guinea pig; Sensitization; Transdermal

Indexed keywords

NALTREXOL; PHENYLENEDIAMINE; RADAFAXINE;

ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; ERYTHEMA; GUINEA PIG; NONHUMAN; PRIORITY JOURNAL; SKIN IRRITATION; SKIN SENSITIZATION; STEADY STATE; TOBACCO DEPENDENCE;

ADMINISTRATION, CUTANEOUS; ALCOHOL-RELATED DISORDERS; ANIMALS; BUPROPION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DELIVERY SYSTEMS; FEMALE; GUINEA PIGS; MALE; MASS SPECTROMETRY; MOLECULAR STRUCTURE; NALTREXONE; PRODRUGS; SKIN; SKIN ABSORPTION; SKIN IRRITANCY TESTS; SMOKING CESSATION;

EID: 41349091213     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.01.006     Document Type: Article

References (32)

1. Belson M.G., and Kelley T.R. Bupropion exposures: clinical manifestations and medical outcome. J. Emerg. Med. 23 (2002) 223-230
2. Bonina F.P., Puglia C., Barbuzzi T., de Caprariis P., Palagiano F., Rimoli M.G., and Saija A. In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur. J. Pharm. Sci. 14 (2001) 123-134
3. Buehler E.V. Delayed contact hypersensitivity in the guinea pig. Arch. Dermatol. 91 (1965) 171-177
4. Buehler E.V. Occlusive patch method for skin sensitization in guinea pigs: the Buehler method. Food Chem. Toxicol. 32 (1994) 97-101
5. Cynkowska G., Cynkowski T., Al-Ghananeem A.A., Guo H., Ashton P., and Crooks P.A. Novel antiglaucoma prodrugs and codrugs of ethacrynic acid. Bioorg. Med. Chem. Lett. 15 (2005) 3524-3527
6. Faull A.W., Brewster A.G., Brown G.R., Smithers M.J., and Jackson R. Dual-acting thromboxane receptor antagonist/synthase inhibitors: synthesis and biological properties of [2-substituted-4-(3-pyridyl)-1,3-dioxan-5-yl] alkenoic acids. J. Med. Chem. 38 (1995) 686-694
7. Ferrari A., Bertolotti M., Dell'Utri A., Avico U., and Sternieri E. Serum time course of naltrexone and 6 beta-naltrexol levels during long-term treatment in drug addicts. Drug Alcohol Depend. 52 (1998) 211-220
8. Frosch D.L., Shoptaw S., Nahom D., and Jarvik M.E. Associations between tobacco smoking and illicit drug use among methadone-maintained opiate-dependent individuals. Exp. Clin. Psychopharmacol. 8 (2000) 97-103
9. Hamad M.O., Kiptoo P.K., Stinchcomb A.L., and Crooks P.A. Synthesis and hydrolytic behavior of two novel tripartate codrugs of naltrexone and 6-beta-naltrexol with hydroxybupropion as potential alcohol abuse and smoking cessation agents. Bioorg. Med. Chem. 14 (2006) 7051-7061
10. Hewitt P.G., Perkins J., and Hotchkiss S.A. Metabolism of fluroxypyr, fluroxypyr methyl ester, and the herbicide fluroxypyr methylheptyl ester. I. During percutaneous absorption through fresh rat and human skin in vitro. Drug Metab. Dispos. 28 (2000) 748-754
11. Hussain M.A., Aungst B.J., Koval C.A., and Shefter E. Improved buccal delivery of opioid analgesics and antagonists with bitterless prodrugs. Pharm. Res. 5 (1988) 615-618
12. Johnston J.A., Fiedler-Kelly J., Glover E.D., Sachs D.P., Grasela T.H., and DeVeaugh-Geiss J. Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res. 3 (2001) 131-140
13. Kiptoo P.K., Hamad M.O., Crooks P.A., and Stinchcomb A.L. Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxybupropion. J. Control. Release 113 (2006) 137-145
14. Kranzler H.R., Modesto-Lowe V., and Van Kirk J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 22 (2000) 493-503
15. McCaul M.E., Wand G.S., Rohde C., and Lee S.M. Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers. Alcohol Clin. Exp. Res. 24 (2000) 1385-1391
16. Meyer M.C., Straughn A.B., Lo M.W., Schary W.L., and Whitney C.C. Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J. Clin. Psychiatry 45 (1984) 15-19
17. Otagiri M., Imai T., and Fukuhara A. Improving the pharmacokinetic and pharmacodynamic properties of a drug by chemical conversion to a chimera drug. J. Control. Release 62 (1999) 223-229
18. Paudel K.S., Nalluri B.N., Hammell D.C., Valiveti S., Kiptoo P., Hamad M.O., Crooks P.A., and Stinchcomb A.L. Transdermal delivery of naltrexone and its active metabolite 6-beta-naltrexol in human skin in vitro and guinea pigs in vivo. J. Pharm. Sci. 94 (2005) 1965-1975
19. Raehal K.M., Lowery J.J., Bhamidipati C.M., Paolino R.M., Blair J.R., Wang D., Sadee W., and Bilsky E.J. In vivo characterization of 6-beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. J. Pharmacol. Exp. Ther. 313 (2005) 1150-1162
20. Rothenberg J.L., Sullivan M.A., Church S.H., Seracini A., Collins E., Kleber H.D., and Nunes E.V. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J. Subst. Abuse Treat. 23 (2002) 351-360
21. Scheuplein R.J. Mechanism of percutaneous absorption. II. Transient diffusion and the relative importance of various routes of skin penetration. J. Invest. Dermatol. 48 (1967) 79-88
22. Scheuplein R.J., and Bronaugh R.L. Percutaneous absorption. In: Goldsmith L.A. (Ed). Biochemistry and Physiology of the Skin vol. 1 (1983), Oxford University Press, Oxford 1255-1294
23. Schmid-Grendelmeier P., Pokorny R., Gasser U.E., and Richarz U. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers. Curr. Med. Res. Opin. 22 (2006) 501-509
24. Schroeder D.H. Metabolism and kinetics of bupropion. J. Clin. Psychiatry 44 (1983) 79-81
25. Sutinen R., Paronen P., Saano V., and Urtti A. Water-activated, pH-controlled patch in transdermal administration of timolol. II. Drug absorption and skin irritation. Eur. J. Pharm. Sci. 11 (2000) 25-31
26. Valiveti S., Nalluri B.N., Hammell D.C., Paudel K.S., and Stinchcomb A.L. Development and validation of a liquid chromatography-mass spectrometry method for the quantitation of naltrexone and 6-beta-naltrexol in guinea pig plasma. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 810 (2004) 259-267
27. Verebey K., Volavka J., Mule S.J., and Resnick R.B. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin. Pharmacol. Ther. 20 (1976) 315-328
28. Volpicelli J.R. Naltrexone in alcohol dependence. Lancet 346 (1995) 456
29. Volpicelli J.R., Alterman A.I., Hayashida M., and O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 49 (1992) 876-880
30. Volpicelli J.R., Rhines K.C., Rhines J.S., Volpicelli L.A., Alterman A.I., and O'Brien C.P. Naltrexone and alcohol dependence. Role of subject compliance. Arch. Gen. Psychiatry 54 (1997) 737-742
31. Wallace S.M., and Barnett G. Pharmacokinetic analysis of percutaneous absorption: evidence of parallel penetration pathways for methotrexate. J. Pharmacokinet. Biopharm. 6 (1978) 315-325
32. Yu C.D., Fox J.L., Ho N.F., and Higuchi W.I. Physical model evaluation of topical prodrug delivery-simultaneous transport and bioconversion of vidarabine-5′-valerate. II. Parameter determinations. J. Pharm. Sci. 68 (1979) 1347-1357